Valuation
- Market cap
- 85,323,000
- Revenue TTM
- $120,770,000
- Net income TTM
- $32,690,000
- PE ratio
- 0.00
- Forward PE
- —
- Profit margin
- 27.07%
- Debt to equity
- 0.00
Trading
- Volume
- 85,700
- Avg volume
- 49,882
- Day's range
- $8.25 – $9.68
- Shares out
- 10,038,000
- Stochastic %K
- 30%
- Beta
- 0.10
- Analysts
- Sell
- Price target
- $13.67
Company profile
Atara Biotherapeutics, Inc. engages in the development of transformative therapies for patients with cancer and autoimmune disease in the United States and internationally. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) with post-transplant lymphoproliferative disease, as well as other EBV-driven diseas...
Show more
Atara Biotherapeutics, Inc. engages in the development of transformative therapies for patients with cancer and autoimmune disease in the United States and internationally. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) with post-transplant lymphoproliferative disease, as well as other EBV-driven diseases. It also develops ATA3219, an allogeneic CAR T targeting CD19 intended to target B-cell malignancies and autoimmune diseases. The company has research collaboration agreements with Memorial Sloan Kettering Cancer Center, and Council of the Queensland Institute of Medical Research. Atara Biotherapeutics, Inc. was incorporated in 2012 and is headquartered in Thousand Oaks, California.
- Industry
- Biotechnology
- Sector
- Healthcare
- Phone
- 805 623 4211
- Website
- https://www.atarabio.com
- Address
- 1280 Rancho Conejo Blvd, Thousand Oaks, United States
Latest news
No headlines yet.
